Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Purchased by Wells Fargo & Company MN

Wells Fargo & Company MN raised its position in Fate Therapeutics, Inc. (NASDAQ:FATE) by 56.3% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 92,395 shares of the biopharmaceutical company’s stock after buying an additional 33,284 shares during the quarter. Wells Fargo & Company MN owned about 0.08% of Fate Therapeutics worth $152,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. acquired a new stake in Fate Therapeutics in the fourth quarter valued at about $40,000. FPC Investment Advisory Inc. acquired a new stake in shares of Fate Therapeutics in the 4th quarter valued at approximately $44,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Fate Therapeutics in the fourth quarter valued at approximately $58,000. Intech Investment Management LLC grew its holdings in Fate Therapeutics by 27.5% during the fourth quarter. Intech Investment Management LLC now owns 39,443 shares of the biopharmaceutical company’s stock worth $65,000 after acquiring an additional 8,497 shares during the period. Finally, SG Americas Securities LLC raised its position in Fate Therapeutics by 30.6% in the fourth quarter. SG Americas Securities LLC now owns 44,874 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 10,511 shares in the last quarter. Hedge funds and other institutional investors own 97.54% of the company’s stock.

Fate Therapeutics Stock Up 1.0 %

NASDAQ FATE opened at $1.04 on Friday. The stock has a market cap of $119.19 million, a price-to-earnings ratio of -0.63 and a beta of 2.32. Fate Therapeutics, Inc. has a fifty-two week low of $0.66 and a fifty-two week high of $5.92. The business has a fifty day moving average of $1.01 and a 200-day moving average of $1.57.

Fate Therapeutics (NASDAQ:FATE) last released its earnings results on Wednesday, March 5th. The biopharmaceutical company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.13. Fate Therapeutics had a negative return on equity of 45.88% and a negative net margin of 1,325.43%. The firm had revenue of $1.86 million during the quarter, compared to analyst estimates of $1.57 million. As a group, analysts anticipate that Fate Therapeutics, Inc. will post -1.63 EPS for the current year.

Wall Street Analyst Weigh In

FATE has been the topic of several research analyst reports. Wedbush restated a “neutral” rating and set a $5.00 target price on shares of Fate Therapeutics in a research report on Thursday, March 6th. Stifel Nicolaus lowered their target price on shares of Fate Therapeutics from $5.00 to $3.00 and set a “hold” rating on the stock in a research report on Thursday, March 6th. StockNews.com downgraded shares of Fate Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, March 11th. Wells Fargo & Company dropped their price objective on Fate Therapeutics from $5.00 to $4.00 and set an “equal weight” rating for the company in a research note on Thursday, March 6th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Fate Therapeutics in a research report on Thursday, March 6th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $5.43.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.